Immediate Urologic Evaluation for Priapism

Diagnostic Approach

The American Urological Association recommends performing corporal blood gas analysis to determine whether priapism is ischemic or non-ischemic, as this distinction determines the urgency and type of intervention needed 1, 2
Ischemic priapism is characterized by PO₂ <30 mmHg, PCO₂ >60 mmHg, and pH <7.25, while non-ischemic priapism is characterized by PO₂ >90 mmHg, PCO₂ <40 mmHg, and pH 7.40 3, 4
Physical examination findings for ischemic priapism include completely rigid corpora cavernosa with severe pain, while non-ischemic priapism is characterized by partial tumescence without full rigidity, typically painless 3, 5, 1

The European Association of Urology recommends immediate intracavernosal phenylephrine with corporal aspiration as the first-line treatment for ischemic priapism, with success rates of 43-81% when combined 4, 5
Phenylephrine concentration should be 100-500 mcg/mL, with a maximum dose of 1000 mcg within the first hour 4
Aspiration with or without irrigation should accompany phenylephrine injection 6, 4

The American Urological Association recommends initial management with observation for up to 4 weeks, as non-ischemic priapism is not a medical emergency and fistulas may close spontaneously 1, 7
If priapism persists after observation and the patient desires treatment, penile duplex Doppler ultrasound should be performed to identify fistula location, followed by percutaneous fistula embolization as first-line therapy 1, 7

The duration of ischemic priapism directly correlates with erectile dysfunction risk, with <24 hours having a reasonable chance of erectile function preservation, 24-36 hours having a significantly increased risk, and >36 hours having a high likelihood of permanent erectile dysfunction 4, 3

The American Urological Association recommends immediately administering intracavernosal phenylephrine with corporal aspiration as first-line treatment for acute ischemic priapism, regardless of underlying conditions like sickle cell disease or leukemia 8, 9
Patients should present for urologic evaluation when priapism exceeds 4 hours to prevent permanent corporal damage and erectile dysfunction 9, 10

The standard urologic approach takes absolute priority over hematologic interventions in patients with sickle cell disease or leukemia 8, 9, 11
Exchange transfusion should NOT be used as primary treatment for acute ischemic priapism in SCD patients 10, 12
Standard sickle cell assessment and interventions should occur concurrent with (not instead of) urologic intervention 9, 11

The American Urological Association suggests preventative strategies for patients with recurrent episodes, including PDE5 inhibitors (tadalafil or sildenafil), ketoconazole with prednisone, hydroxyurea (for SCD patients), and home self-injection of phenylephrine on as-needed basis 11, 13

Patients must be informed that hormonal regulators (ketoconazole, cyproterone acetate) may impair fertility and sexual function, and have potential side effects including fatigue, hot flashes, breast tenderness, mood changes, and erectile dysfunction 8, 11, 13